Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra PharmaceuticalsApr 8 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

One poster will present Phase 1 multi-dose clinical results for CEM-101, a next-generation oral and intravenous macrolide.  Four additional presentations on CEM-101 will present results on the compound's in vitro activity against a variety of bacterial pathogens, including drug-resistant strains.  A sixth poster will present in vitro activity of TAKSTA (CEM-102) against European gram positive isolates, including staphylococci, streptococci and enterococci.  TAKSTA (sodium fusidate) is a highly active antibiotic against methicillin-resistant Staphylococcus aureus (MRSA).  It is in development in the U.S. for acute bacterial skin structure infections (aBSSI) employing a proprietary front-loading oral dosing regimen.  All six posters will be presented during the poster session scheduled for 12:30 to 1:30 p.m. CET on Sunday, April 11.

Cempra Pharmaceuticals ECCMID 2010 Schedule At-A-Glance

Sunday, April 11, 2010

• Poster presentation: "CEM-101, a novel fluoroketolide, tested against European clinical isolates from 2009 (first-year surveillance results)"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 901

R. Jones, D. Farrell, H. Sader, M. Stilwell, M. Castaheira (JMI Laboratories, North Liberty, IA, USA)

• Poster Presentation: "Multiple dose pharmacokinetics and safety of CEM-101, a new fluoroketolide, in healthy subjects"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 902

J.G. Still, K. Clark, T. Degenhardt, D. Scott, P. Fernandes (Cempra Pharmaceuticals, Chapel Hill, USA)

• Poster Presentation: "CEM-101, a novel ketolide; in vitro activity against Legionella pneumophila"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 903

J. Dubois(1), P. Fernandes(2) ((1)M360, Sherbrooke, Canada, (2)Cempra Pharmaceuticals Inc., Chapel Hill, USA)

• Poster Presentation: "CEM-101, a novel ketolide, in vitro activity against resistant strains of Streptococcus pnuemoniae and Haemophilus influenza"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 904

J. Dubois(1), P. Fernandes(2) ((1)M360, Sherbrooke, Canada, (2)Cempra Pharmaceuticals Inc., Chapel Hill, USA)

• Poster Presentation: "Expanded studies of CEM-101, a novel fluoroketolide, tested against invasive isolates of N. meningitidis, including flouroquinolone-non-susceptible resistant strains"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 905

R. Jones, D. Biedenbach, L. Woosley, G. Gerken, M. Castaheira (JMI Laboratories, North Liberty, IA, USA)

• Poster Presentation: "CEM-102 (fusidic acid) in vitro activity and evaluation of molecular resistance mechanisms among European Gram-positive isolates, 2008-2009"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 906

M. Castanheira, D. Farrell, M. Janechek, R. Jones

(JMI Laboratories, North Liberty, IA, USA)